cp-55,940 has been researched along with Multiple Sclerosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JZ; Chen, LL; Han, S; Pu, JB; Qian, HY; Xie, X; Zhang, FF | 1 |
| Carrillo-Salinas, FJ; Fernández-Ruiz, J; Franco, R; Gómez-Cañas, M; Goya, P; Guaza, C; Hurst, DP; Jagerovic, N; Lagartera, L; Morales, P; Navarro, G; Pazos, R; Reggio, PH | 1 |
| Cheng, J; Duan, W; Hua, T; Li, F; Liu, ZJ; Nie, H; Sun, Y; Wang, H; Wu, M; Xu, Y; Yang, L; Zhang, T; Zhang, Z | 1 |
3 other study(ies) available for cp-55,940 and Multiple Sclerosis
| Article | Year |
|---|---|
Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Ligands; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Multiple Sclerosis; Quantitative Structure-Activity Relationship; Quinolines; Receptor, Cannabinoid, CB2 | 2015 |
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.
Topics: Dose-Response Relationship, Drug; HEK293 Cells; Humans; Models, Molecular; Molecular Structure; Multiple Sclerosis; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2016 |
Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
Topics: Animals; Cannabinoids; Carbon; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Multiple Sclerosis; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Silicon; Structure-Activity Relationship | 2021 |